This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaba, S. A.
Right arrow Articles by Todd, C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaba, S. A.
Right arrow Articles by Todd, C. W.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2008, p. 1674-1683, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00164-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Immune Responses of Mice with Different Genetic Backgrounds to Improved Multiepitope, Multitarget Malaria Vaccine Candidate Antigen FALVAC-1A {triangledown}

S. A. Kaba,1,{dagger} A. Price,1,2 Z. Zhou,1,2 V. Sundaram,1 P. Schnake,1 I. F. Goldman,1 A. A. Lal,1 V. Udhayakumar,1 and C. W. Todd1,2*

Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341,1 Atlanta Research and Education Foundation, Decatur, Georgia 300332

Received 7 May 2008/ Returned for modification 11 June 2008/ Accepted 29 August 2008

FALVAC-1A is a second-generation multitarget, multiepitope synthetic candidate vaccine against Plasmodium falciparum, incorporating elements designed to yield a stable and immunogenic molecule. Characteristics of the immunogenicity of FALVAC-1A were evaluated in congenic (H-2b, H-2k, and H-2d) and outbred strains of mice. The influences of four adjuvants (aluminum phosphate, QS-21, Montanide ISA-720, and copolymer CRL-1005) on different aspects of the immune response were also assessed. FALVAC-1A generated strong antibody responses in all mouse strains. The highest mean enzyme-linked immunosorbent assay (ELISA) antibody concentrations against FALVAC-1A were observed in the outbred ICR mice, followed by B10.BR, B10.D2, and C57BL/6 mice, though this order varied for the different adjuvants, with no statistical differences between mouse strains. In all mouse strains, the highest anti-FALVAC-1A antibody titers in ELISAs were induced by FALVAC-1A in copolymer and ISA-720 formulations, followed by QS-21 and AlPO4. These antibodies were of all four subclasses, though immunoglobulin G1 (IgG1) predominated, with the exception of FALVAC-1A with the QS-21 adjuvant, which induced predominantly IgG2c responses. Both sporozoites and blood stages of P. falciparum were recognized by anti-FALVAC-1A sera in the immunofluorescence assay. In addition to antibody, cellular immune responses were detected; these responses were studied by examining spleen cells producing gamma interferon and interleukin-4 in enzyme-linked immunospot assays. In summary, FALVAC-1A was found to be highly immunogenic and elicited functionally relevant antibodies that can recognize sporozoites and blood-stage parasites in diverse genetic backgrounds.


* Corresponding author. Mailing address: Division of Parasitic Diseases, 4770 Buford Highway, MS F-36, Centers for Disease Control and Prevention, Atlanta, GA 30341. Phone: (770) 488-4526. Fax: (770) 488-4253. E-mail: ckt1{at}cdc.gov

{triangledown} Published ahead of print on 10 September 2008.

{dagger} Present address: Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD 20910.


Clinical and Vaccine Immunology, November 2008, p. 1674-1683, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00164-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.